The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity

Nathan, 1992, Insulinotropic action of glucagonlike peptide-I-(7–37) in diabetic and nondiabetic subjects, Diabetes Care, 15, 270, 10.2337/diacare.15.2.270 Zander, 2002, Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study, Lancet, 359, 824, 10.1016/S0140-6736(02)07952-7 Stoffers, 2000, Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas, Diabetes, 49, 741, 10.2337/diabetes.49.5.741 Perfetti, 2000, Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats, Endocrinology, 141, 4600, 10.1210/en.141.12.4600 Kieffer, 1995, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, Endocrinology, 136, 3585, 10.1210/en.136.8.3585 Hupe-Sodmann, 1997, Endoproteolysis of glucagon-like peptide (GLP)-1 (7–36) amide by ectopeptidases in RINm5F cells, Peptides, 18, 625, 10.1016/S0196-9781(97)00123-X Eng, 1992, Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas, J. Biol. Chem., 267, 7402, 10.1016/S0021-9258(18)42531-8 Hansen, 1999, Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine, Endocrinology, 140, 5356, 10.1210/en.140.11.5356 Hupe-Sodmann, 1995, Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides, Regul. Pept., 58, 149, 10.1016/0167-0115(95)00063-H Greig, 1999, Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations, Diabetologia, 42, 45, 10.1007/s001250051111 Young, 1999, Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta), Diabetes, 48, 1026, 10.2337/diabetes.48.5.1026 Edwards, 2001, Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers, Am. J. Physiol. Endocrinol. Metab., 281, E155, 10.1152/ajpendo.2001.281.1.E155 Egan, 2002, The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes, J. Clin. Endocrinol. Metab., 87, 1282, 10.1210/jc.87.3.1282 Montrose-Rafizadeh, 1997, High potency antagonists of the pancreatic glucagon-like peptide-1 receptor, J. Biol. Chem., 272, 21201, 10.1074/jbc.272.34.21201 Parkes, 2001, Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1, Drug Dev. Res., 53, 260, 10.1002/ddr.1195 Deacon, 1998, Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity, Diabetologia, 41, 271, 10.1007/s001250050903 Burcelin, 1999, Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1, Metabolism, 48, 252, 10.1016/S0026-0495(99)90043-4 Doyle, 2001, Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent, Endocrinology, 142, 4462, 10.1210/en.142.10.4462 Delean, 1988 Neidigh, 2001, Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states, Biochemistry, 40, 13188, 10.1021/bi010902s